Cargando…

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?

It is a well-accepted fact that obesity and diabetes increase the risk of incidence of different cancers and their progression, leading to a decrease in the quality of life among affected cancer patients. In addition to decreasing the risk of cancers, maintaining a healthy body mass index (BMI)/body...

Descripción completa

Detalles Bibliográficos
Autores principales: Samuel, Samson Mathews, Varghese, Elizabeth, Kubatka, Peter, Büsselberg, Dietrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687454/
https://www.ncbi.nlm.nih.gov/pubmed/36358930
http://dx.doi.org/10.3390/biom12111580
_version_ 1784836009254453248
author Samuel, Samson Mathews
Varghese, Elizabeth
Kubatka, Peter
Büsselberg, Dietrich
author_facet Samuel, Samson Mathews
Varghese, Elizabeth
Kubatka, Peter
Büsselberg, Dietrich
author_sort Samuel, Samson Mathews
collection PubMed
description It is a well-accepted fact that obesity and diabetes increase the risk of incidence of different cancers and their progression, leading to a decrease in the quality of life among affected cancer patients. In addition to decreasing the risk of cancers, maintaining a healthy body mass index (BMI)/body weight and/or blood glucose levels within the normal range critically impacts the response to anti-cancer therapy among affected individuals. A cancer patient managing their body weight and maintaining blood glucose control responds better to anti-cancer therapy than obese individuals and those whose blood glucose levels remain higher than normal during therapeutic intervention. In some cases, anti-diabetic/glucose-lowering drugs, some of which are also used to promote weight loss, were found to possess anti-cancer potential themselves and/or support anti-cancer therapy when used to treat such patients. On the other hand, certain glucose-lowering drugs promoted the cancer phenotype and risked cancer progression when used for treatment. Tirzepatide (TRZD), the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide/gastric inhibitory peptide (GIP) agonist, has recently gained interest as a promising injectable drug for the treatment of type 2 diabetes and was approved by the FDA after successful clinical trials (SURPASS 1/2/3/4 and 5, NCT03954834, NCT03987919, NCT03882970, NCT03730662, and NCT04039503). In addition, the reports from the SURMOUNT-1 clinical trial (NCT04184622) support the use of TRZD as an anti-obesity drug. In the current review article, we examine the possibility and molecular mechanisms of how TRZD intervention could benefit cancer therapeutics or increase the risk of cancer progression when used as an anti-diabetic drug in diabetic patients.
format Online
Article
Text
id pubmed-9687454
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96874542022-11-25 Tirzepatide—Friend or Foe in Diabetic Cancer Patients? Samuel, Samson Mathews Varghese, Elizabeth Kubatka, Peter Büsselberg, Dietrich Biomolecules Review It is a well-accepted fact that obesity and diabetes increase the risk of incidence of different cancers and their progression, leading to a decrease in the quality of life among affected cancer patients. In addition to decreasing the risk of cancers, maintaining a healthy body mass index (BMI)/body weight and/or blood glucose levels within the normal range critically impacts the response to anti-cancer therapy among affected individuals. A cancer patient managing their body weight and maintaining blood glucose control responds better to anti-cancer therapy than obese individuals and those whose blood glucose levels remain higher than normal during therapeutic intervention. In some cases, anti-diabetic/glucose-lowering drugs, some of which are also used to promote weight loss, were found to possess anti-cancer potential themselves and/or support anti-cancer therapy when used to treat such patients. On the other hand, certain glucose-lowering drugs promoted the cancer phenotype and risked cancer progression when used for treatment. Tirzepatide (TRZD), the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide/gastric inhibitory peptide (GIP) agonist, has recently gained interest as a promising injectable drug for the treatment of type 2 diabetes and was approved by the FDA after successful clinical trials (SURPASS 1/2/3/4 and 5, NCT03954834, NCT03987919, NCT03882970, NCT03730662, and NCT04039503). In addition, the reports from the SURMOUNT-1 clinical trial (NCT04184622) support the use of TRZD as an anti-obesity drug. In the current review article, we examine the possibility and molecular mechanisms of how TRZD intervention could benefit cancer therapeutics or increase the risk of cancer progression when used as an anti-diabetic drug in diabetic patients. MDPI 2022-10-28 /pmc/articles/PMC9687454/ /pubmed/36358930 http://dx.doi.org/10.3390/biom12111580 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Samuel, Samson Mathews
Varghese, Elizabeth
Kubatka, Peter
Büsselberg, Dietrich
Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
title Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
title_full Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
title_fullStr Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
title_full_unstemmed Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
title_short Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
title_sort tirzepatide—friend or foe in diabetic cancer patients?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687454/
https://www.ncbi.nlm.nih.gov/pubmed/36358930
http://dx.doi.org/10.3390/biom12111580
work_keys_str_mv AT samuelsamsonmathews tirzepatidefriendorfoeindiabeticcancerpatients
AT vargheseelizabeth tirzepatidefriendorfoeindiabeticcancerpatients
AT kubatkapeter tirzepatidefriendorfoeindiabeticcancerpatients
AT busselbergdietrich tirzepatidefriendorfoeindiabeticcancerpatients